Patents Assigned to Genentech
  • ANTI-HYPUSINE ANTIBODIES AND USES THEREOF
    Publication number: 20180328938
    Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.
    Type: Application
    Filed: February 27, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Qianting ZHAI, Paul J. CARTER
  • Therapeutic compounds and methods of use thereof
    Patent number: 10125098
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 13, 2018
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • Peptidomimetic compounds and antibody-drug conjugates thereof
    Patent number: 10124069
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: November 13, 2018
    Assignee: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • Multispecific antibodies
    Patent number: 10118970
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies. In general, the multispecific antibodies are made by methods involving the steps of altering the nucleic acid sequence encoding the light chain variable domain (VL) of an antibody that binds a first epitope, and selecting a multispecific antibody capable of binding the first and a second epitope.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Jenny M. Bostrom
  • ANTI-IL-17A AND IL-17F CROSS REACTIVE ANTIBODY VARIANTS AND COMPOSITIONS COMPRISING AND METHODS OF MAKING AND USING SAME
    Publication number: 20180312584
    Abstract: The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 1, 2018
    Applicant: Genentech, Inc.
    Inventors: GALAHAD DEPERALTA, AARON WECKSLER, MELISSA ALVAREZ
  • METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
    Publication number: 20180312585
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Application
    Filed: February 22, 2018
    Publication date: November 1, 2018
    Applicant: Genentech, Inc.
    Inventors: X. Christopher Yu, Atia Naim, Christopher A. Teske, Martin Vanderlaan
  • ANTI-GPC3 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20180312602
    Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 7, 2018
    Publication date: November 1, 2018
    Applicant: GENENTECH, INC.
    Inventors: Paul Polakis, Youjun Chen
  • ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20180312586
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 12, 2018
    Publication date: November 1, 2018
    Applicant: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Anti-Tau antibodies and methods of use
    Patent number: 10112990
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignees: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Anti-jagged antibodies and methods of use
    Patent number: 10113002
    Abstract: The disclosure provides anti-Jagged antibodies and methods of using the same.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • Benzoxazepin oxazolidinone compounds and methods of use
    Patent number: 10112932
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Methods of producing two chain proteins in bacteria
    Patent number: 10112994
    Abstract: Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: October 30, 2018
    Assignee: GENENTECH, INC.
    Inventors: James Giulianotti, Dorothea Reilly
  • COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20180303936
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
    Type: Application
    Filed: February 1, 2018
    Publication date: October 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Jeanne CHEUNG, Jeong KIM
  • 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180305355
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
  • HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING
    Publication number: 20180305462
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Application
    Filed: April 30, 2018
    Publication date: October 25, 2018
    Applicant: GENENTECH, INC.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess
  • TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180298033
    Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20180298015
    Abstract: Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: June 21, 2018
    Publication date: October 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Marian C. Bryan, Alberto Gobbi, James Richard Kiefer, JR., Aleksandr Kolesnikov, Alan G. Olivero, Joy Drobnick, Jun Liang, Naomi Rajapaksa, Chudi Ndubaku, Jianwen Feng
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180297997
    Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Rongbao Hua, Terry Kellar, Wei Li, Paul Gibbons, Mark Edward Zak
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20180296470
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: October 18, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • Systems and methods for two-dimensional chromatography
    Patent number: 10101306
    Abstract: Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)-supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: October 16, 2018
    Assignee: GENENTECH, INC.
    Inventors: Cadapakam Venkatramani, Mohammad Al-Sayah